“扎根中国的信心更足了”

Core Insights - The article highlights Beijing's efforts to enhance high-level openness to the outside world, exemplified by AstraZeneca's successful approval for data export compliance in December 2025 [1] - AstraZeneca's commitment to China is reinforced by a favorable policy environment, making Beijing a key strategic location for the company [1] Company Developments - AstraZeneca has received approval for two innovative drugs for rare diseases in the first half of 2025, facilitating temporary importation of urgently needed clinical drugs [1] - Since entering China in 1993, AstraZeneca has invested over $5 billion, with China becoming its second-largest market globally [1] - The workforce in Beijing is expected to grow to over 1,700 employees in the near future [1] Industry Context - Beijing is actively promoting a more open ecosystem for global resources, focusing on data flow, drug clearance, institutional innovation, and ecological cultivation [1] - Over the past five years, Beijing has implemented more than 400 reform and opening-up tasks approved by the State Council, resulting in the establishment of over 9,000 foreign-funded enterprises [1]